Exenatide Increases IL-1RA Concentration and Induces Nrf-2‒Keap-1‒Regulated Antioxidant Enzymes: Relevance to β-Cell Function.

Dandona P, Ghanim H, Abuaysheh S, Green K, Dhindsa S, Makdissi A, Batra M, Kuhadiya ND, Chaudhuri A

The Journal of clinical endocrinology and metabolism1 Mar 2018Cited by 15 (Europe PMC)

PMID29346597DOI10.1210/jc.2017-02343PepBankPUB-29346597

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialMechanism
In patients with obesity and T2DM, exenatide increased plasma IL-1RA concentration.
In plain wordsIn patients with obesity and diabetes, exenatide increased an anti-inflammatory protein in blood.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseIL-1RA concentration
Study
n = 24
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 μg twice a day · 12 weeksAs given in this study (human).
Measurements
IL-1RA increase
61%
exenatide
IL-1RA concentration
318 pg/mL
before exenatide
IL-1RA concentration
456 pg/mL
after exenatide
Source sentences
Summary
Exenatide increased IL-1RA concentration by 61% (from 318 ± 53 to 456 ± 88 pg/mL; P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with obesity and type 2 diabetes receiving combined oral and insulin therapy were randomly assigned to receive either exenatide 10 μg or placebo twice a day for 12 weeks.
Report a problemFND-2934659701
02HumanRandomized controlled trialMechanism
In patients with obesity and T2DM, exenatide suppressed mononuclear-cell Keap-1 protein.
In plain wordsIn patients with obesity and diabetes, exenatide reduced Keap-1 protein in blood immune cells.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseKeap-1 protein
Study
n = 24
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 μg twice a day · 12 weeksAs given in this study (human).
Source sentences
Summary
Exenatide treatment also suppressed Keap-1 protein (P < 0.05) and increased messenger RNA expression of NQO-1, glutathione S-transferase PI, heme oxygenase-1, and p21 and increased NAD(P)H dehydrogenase [quinone] 1 protein (P < 0.05) in mononuclear cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with obesity and type 2 diabetes receiving combined oral and insulin therapy were randomly assigned to receive either exenatide 10 μg or placebo twice a day for 12 weeks.
Report a problemFND-2934659702
03HumanRandomized controlled trialMechanism
In patients with obesity and T2DM, exenatide increased mononuclear-cell NQO-1 mRNA expression.
In plain wordsIn patients with obesity and diabetes, exenatide increased NQO-1 gene activity in blood immune cells.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNQO-1 mRNA
Study
n = 24
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 μg twice a day · 12 weeksAs given in this study (human).
Source sentences
Summary
Exenatide treatment also suppressed Keap-1 protein (P < 0.05) and increased messenger RNA expression of NQO-1, glutathione S-transferase PI, heme oxygenase-1, and p21 and increased NAD(P)H dehydrogenase [quinone] 1 protein (P < 0.05) in mononuclear cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with obesity and type 2 diabetes receiving combined oral and insulin therapy were randomly assigned to receive either exenatide 10 μg or placebo twice a day for 12 weeks.
Report a problemFND-2934659703
04HumanRandomized controlled trialMechanism
In patients with obesity and T2DM, exenatide increased mononuclear-cell glutathione S-transferase PI mRNA expression.
In plain wordsIn patients with obesity and diabetes, exenatide increased glutathione S-transferase PI gene activity in blood immune cells.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGlutathione S-transferase PI mRNA
Study
n = 24
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 μg twice a day · 12 weeksAs given in this study (human).
Source sentences
Summary
Exenatide treatment also suppressed Keap-1 protein (P < 0.05) and increased messenger RNA expression of NQO-1, glutathione S-transferase PI, heme oxygenase-1, and p21 and increased NAD(P)H dehydrogenase [quinone] 1 protein (P < 0.05) in mononuclear cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with obesity and type 2 diabetes receiving combined oral and insulin therapy were randomly assigned to receive either exenatide 10 μg or placebo twice a day for 12 weeks.
Report a problemFND-2934659704
05HumanRandomized controlled trialMechanism
In patients with obesity and T2DM, exenatide increased mononuclear-cell heme oxygenase-1 mRNA expression.
In plain wordsIn patients with obesity and diabetes, exenatide increased heme oxygenase-1 gene activity in blood immune cells.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHeme oxygenase-1 mRNA
Study
n = 24
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 μg twice a day · 12 weeksAs given in this study (human).
Source sentences
Summary
Exenatide treatment also suppressed Keap-1 protein (P < 0.05) and increased messenger RNA expression of NQO-1, glutathione S-transferase PI, heme oxygenase-1, and p21 and increased NAD(P)H dehydrogenase [quinone] 1 protein (P < 0.05) in mononuclear cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with obesity and type 2 diabetes receiving combined oral and insulin therapy were randomly assigned to receive either exenatide 10 μg or placebo twice a day for 12 weeks.
Report a problemFND-2934659705
06HumanRandomized controlled trialMechanism
In patients with obesity and T2DM, exenatide increased mononuclear-cell p21 mRNA expression.
In plain wordsIn patients with obesity and diabetes, exenatide increased p21 gene activity in blood immune cells.
Peptide
Exenatide (exendin-4)
Outcome
Increasep21 mRNA
Study
n = 24
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 μg twice a day · 12 weeksAs given in this study (human).
Source sentences
Summary
Exenatide treatment also suppressed Keap-1 protein (P < 0.05) and increased messenger RNA expression of NQO-1, glutathione S-transferase PI, heme oxygenase-1, and p21 and increased NAD(P)H dehydrogenase [quinone] 1 protein (P < 0.05) in mononuclear cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with obesity and type 2 diabetes receiving combined oral and insulin therapy were randomly assigned to receive either exenatide 10 μg or placebo twice a day for 12 weeks.
Report a problemFND-2934659706
07HumanRandomized controlled trialMechanism
In patients with obesity and T2DM, exenatide increased mononuclear-cell NAD(P)H dehydrogenase [quinone] 1 protein.
In plain wordsIn patients with obesity and diabetes, exenatide increased an antioxidant enzyme protein in blood immune cells.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNAD(P)H dehydrogenase [quinone] 1 protein
Study
n = 24
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 μg twice a day · 12 weeksAs given in this study (human).
Source sentences
Summary
Exenatide treatment also suppressed Keap-1 protein (P < 0.05) and increased messenger RNA expression of NQO-1, glutathione S-transferase PI, heme oxygenase-1, and p21 and increased NAD(P)H dehydrogenase [quinone] 1 protein (P < 0.05) in mononuclear cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with obesity and type 2 diabetes receiving combined oral and insulin therapy were randomly assigned to receive either exenatide 10 μg or placebo twice a day for 12 weeks.
Report a problemFND-2934659707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT01154933

Exeantide in Type 2 Diabetes on Insulin

University at Buffalon = 24Apr 2008 to Nov 2011

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 6 Oct 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.